{"protocolSection":{"identificationModule":{"nctId":"NCT06471933","orgStudyIdInfo":{"id":"NOR-001"},"organization":{"fullName":"Nordberg Medical AB","class":"INDUSTRY"},"briefTitle":"Post Market Clinical Follow up Evaluating the Performance and Safety of Juläine(TM) on Nasolabial Fold Wrinkles","officialTitle":"A Prospective, Single-Arm, Interventional, Multicenter, Post-Market Clinical Follow-up (PMCF) Investigation to Evaluate the Performance and Safety of Injectable Poly-LLactic Acid Dermal Filler for the Treatment of Nasolabial Fold Wrinkles"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2025-06-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-06-30","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-18","studyFirstSubmitQcDate":"2024-06-23","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-23","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nordberg Medical AB","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this post marketing study is to verify clincal performance and safety of CE-marked device Juläine.\n\nThe main objective is to evaluate device performance when used as intended for augmentation of shallow to deep nasolabial folds.\n\nParticipants will:\n\nReceive 3 rounds of treatment and will be followed up for a total of 2 years.","detailedDescription":"The goal of this post marketing study is to verify clincal performance and safety of CE-marked device Juläine.\n\nThe main objective is to evaluate device performance when used as intended for augmentation of shallow to deep nasolabial folds.\n\nParticipants will:\n\nReceive 3 rounds of treatment and will be followed up for a total of 2 years."},"conditionsModule":{"conditions":["Nasolabial Fold"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":59,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Juläine","type":"EXPERIMENTAL","interventionNames":["Device: Juläine"]}],"interventions":[{"type":"DEVICE","name":"Juläine","description":"Dermal filler (PLLA)","armGroupLabels":["Juläine"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Improvement on WSRS of at least 1 grade.","description":"Average improvment of at least 1 grade on the WSRS of the combined left and right NLF score.","timeFrame":"12 months after final injection"}],"secondaryOutcomes":[{"measure":"Percentage of subjects with improvement of at least 1 grade on the WSRS.","description":"Percentage of subjects with an improvement of at least 1 grade on the WSRS of the left and right (mean of the two) NLF at 3, 6 and 24 months after final injection compared to baseline (investigator assessment at all visits, blinded assessment at 12 months).","timeFrame":"Up to 24 months after final injection"},{"measure":"Change in WSRS score","description":"Change in WSRS score of the NLF at 3, 6, 12 and 24 months after final injection compared to baseline.","timeFrame":"Up to 24 months after final injection"},{"measure":"Mean WSRS of <2 at each follow-up time","description":"Proportion of subjects with a mean WSRS of \\<2 at each follow-up time point at 3, 6, 12, and 24 months after final injection.","timeFrame":"Up to 24 months after final injection"},{"measure":"Time to at least one grade improvement in mean WSRS and time to mean WSRS <2.","description":"Time to at least one grade improvement in mean WSRS and time to mean WSRS \\<2.","timeFrame":"Up to 24 months after final injection"},{"measure":"Change Face-Q score of NFL","description":"Change in FACE-Q score of the NLF at 6, 12, and 24 months after final injection compared to baseline.","timeFrame":"Up to 24 months after final injection"},{"measure":"Change in Global Aesthetic in Improvement Scale","description":"Change in Global Aesthetic Improvement Scale (GAIS) scores evaluated by the subject, the investigator and a blinded assessor from 2D facial digital imaging at 6, 12, and 24 months after final injection compared to baseline.","timeFrame":"Up to 24 months after final injection"},{"measure":"Subject Satisfaction Scores","description":"Assessment of Subject Satisfaction Scores at 6, 12, and 24 months after final injection.","timeFrame":"Up to 24 months after final injection"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Signed Informed Consent Form\n2. Male or female, ≥18 years old.\n3. Immune-competent individuals.\n4. Presenting NLF contour deficiencies with a WSRS score between 2 (shallow wrinkle) and 4 (deep wrinkle) on both the left and right side of the face.\n\nExclusion Criteria:\n\nHaving received a prior facial surgery for NLF correction, and/or received any local therapeutic treatment (e.g., dermal fillers). 2. Having received in the past 2 weeks any local therapeutic treatment of the face below zygomatic arch. 3. Pigmentation in NLF or having a history of hypo melanosis. 4. Susceptibility to keloid formation or hypertrophic scarring. 5. History of a known allergic reaction (e.g., any subject allergic to lidocaine or amide anesthetics, has a history of allergy to Gram-positive bacterial protein, or known to be allergic to any of the constituents of the product: PLLA, sodium carboxymethyl cellulose, mannitol, or sodium hyaluronate). 6. History of herpes eruption, or a history of malignant skin disorder, or a history of any other serious disease. 7. Hemorrhagic disease or receiving anti-coagulant therapy. 8. Presenting with acute inflammation, infection, or having a history of chronic or recurrent infection potentially affecting the safety or performance of the device or increasing risk for adverse events.\n\n9. Having received in the past 2 months immunosuppressant or systemic steroid therapy.\n\n10. Having any disease that may affect wound healing, such as connective tissue disorder or serious malnutrition. 11. Female who is pregnant and/or lactating 12. Any other condition that as judged by the investigator may make follow-up or Investigation procedures inappropriate","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"}},"hasResults":false}